Zanidatamab is used when the cancer cannot be removed by surgery and has spread to nearby tissues or other parts of the body.
Similar Posts
Medicines regulator approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only
The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.
M6-C Artificial Cervical Disc, Spinal Kinetics LLC: New monitoring requirements for the risk of osteolysis
The MHRA has conducted an assessment following reports of osteolysis and early device failure in the literature and is issuing new monitoring requirements for patients implanted with the M6-C artificial cervical disc.
Decision: Advertising Investigations: July 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Field Safety Notices: 10 to 14 November 2025
List of Field Safety Notices from 10 to 14 November 2025.
Guidance: Centres of Excellence for Regulatory Science and Innovation (CERSIs)
An initiative to help drive advancements in healthcare, to ensure patients benefit from innovation and new treatments sooner.
MHRA urges public to avoid illegal online weight-loss medicines this New Year
As many people consider lifestyle changes at the start of the year, the Medicines and Healthcare products Regulatory Agency (MHRA) is urging the public to make sure any weight-loss medicines they use are safe, effective and legitimate.